inflammation and glp 1 GLP-1 Receptor Agonists in Obese Patients with Inflammatory Bowel Disease: from Molecular Mechanisms to Clinical Considerations Practical Recommendations for Safe and Effective Use | Current Obesity Reports JCI - GLP-1 and the

Your body reaches into its fat stores and converts them to fuel

Furthermore, the STEP-TEENS trial demonstrated semaglutides effectiveness in reducing BMI and cardiometabolic risks in obese adolescents, suggesting its potential for use in younger populations (40)

Andrews DA, Yang L, Low PS

The dose escalation phase alone takes 16 to 20 weeks for most GLP-1 medications, and meaningful weight loss really begins at therapeutic doses

Combining tirzepatide with lifestyle modificationsincluding a balanced, calorie-appropriate diet and regular physical activityoptimizes treatment outcomes and supports long-term metabolic health